Network meta-analysis compares outcomes of first-line therapies for advanced endometrial cancer, indicating potential treatment preferences.
Prior meta-analysis has suggested a progression-free survival (PFS) advantage for anti-PD1 agents plus chemotherapy (CT) vs anti-PD-L1+CT (excluding PARP inhibitors) in treatment of patients with 1L pMMR primary advanced or recurrent endometrial cancer. In the NRG-GY018 trial (pembrolizumab (PEM)+CT vs. CT), 43% of control patients in the pMMR cohort switched to PEM arm before progression after achieving successful PFS (primary hypothesis) at interim analysis, confounding the subsequent PFS measures.
No takes yet. Share an insight, caveat, or question.
Marth et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: